Upcoming EventsMore >>
DateTitle
10/27/14
Q3 2014 Amgen Earnings Release
10/28/14
8:00 a.m.
through
10/28/14
12:00 p.m. ET
Amgen 2014 Business Review
LocationNew York, NY
Recent NewsMore >>
DateTitle 
10/17/14Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors
THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W. and Linda L. Mahley Distinguished Professor.  "We are pleased to welcome Dr. Sandy Williams to the Amgen Board," said Robert A. Bradway, chairman and chief executive officer of Amgen. "Dr. Williams' deep and distinguished experience in academic medicine and his direct experience in our industry will... 
Printer Friendly Version
10/17/14Amgen Announces 2014 Fourth Quarter Dividend
THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the fourth quarter of 2014. The dividend will be paid on Dec. 5, 2014, to all stockholders of record as of the close of business on Nov. 13, 2014.  About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human... 
Printer Friendly Version
10/17/14Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Amgen Seeks Injunction Related to PCSK9 Inhibitor THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"), and Regeneron Pharmaceuticals, Inc. ("Regeneron") for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned... 
Printer Friendly Version
10/09/14Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of a... 
Printer Friendly Version
What's New
09/30/14
Download Documentation 2003 – 2013 EPS Reconciliation
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
Investor Insights Newsletters
DateTitle
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
04/30/14
Download Documentation Investor Insights Newsletter - Q1 2014
02/11/14
Download Documentation Investor Insights Newsletter - Q4 2013
10/31/13
Download Documentation Investor Insights Newsletter - Q3 2013

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.